Through a series of selective experiments, we evaluated CAR activation profiles, as well as in vitro and in vivo functionality in a xenograft AML model, comparing these with benchmark CD33-CAR-T cells based on ScFv. The gene discussed is CD33; the disease is acute myeloid leukemia.